Clinical performance of the levonorgestrel intra-uterine system in routine use by the UK Family Planning and Reproductive Health Research Network: 12-month report

Journal of Family Planning and Reproductive Health Care

Volumn 26, Issue 3, 2000, Pages 143-147

  Cox, Michael ^a   Blacksell, Sarah ^a  

^a UNIVERSITY OF EXETER   (United Kingdom)

Author keywords

12 month findings; Intra uterine contraception; Levonorgestrel intra uterine system

Indexed keywords

CONTRACEPTIVE AGENT; LEVONORGESTREL; SEX HORMONE;

ACNE; ADULT; AFFECTIVE NEUROSIS; AMENORRHEA; ARTICLE; BREAST DISEASE; CLINICAL TRIAL; CONTRACEPTION; DEPRESSION; DRUG ABSORPTION; DRUG EFFICACY; DYSPAREUNIA; EDEMA; FAMILY PLANNING; FATIGUE; FEMALE; GENERAL PRACTICE; HEADACHE; HEART PALPITATION; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; MAJOR CLINICAL STUDY; MASTALGIA; MENSTRUATION; MULTICENTER STUDY; NAUSEA; OLIGOMENORRHEA; OVARY CYST; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PREGNANCY; PREMENSTRUAL SYNDROME; SEPTICEMIA; TREATMENT FAILURE; UNITED KINGDOM; VAGINA DISCHARGE; VERTIGO; WEIGHT GAIN;

ABORTION, SPONTANEOUS; ADOLESCENT; ADULT; AGE DISTRIBUTION; FAMILY PLANNING SERVICES; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; MIDDLE AGED; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY RATE;

EID: 0033924926     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: 10.1783/147118900101194571     Document Type: Article

References (26)

1. Luukkainen T. The levonorgestrel-releasing IUD. Br J Fam Plann 1993; 19: 221-224.
2. Andersson K, et al. Levonorgestrel-releasing and copper releasing (NovaT) IUDs during five years of use: A randomised comparative trial. Contraception 1994; 49; 56-72.
3. Sivin I, Alvarez, et al. Contraception 1984; 30: 434-456.
4. Indian Council of Medical Research Task Force on IUD.Randomised clinical trials with intra-uterine devices levonotgestrel intra-uterine device (LNG), Cu T380Ag, Cu T220C, Cu T 200B): A 36-month study. Contraception 1989; 39: 37-52.
5. Luukkainen T, Allonen H, et al. Five years experience with levonorgestrel-releasing IUDs. Contraception 1986; 33: 139-148.
6. Sivin I, Stern J, et al. Prolonged intrauterine contraception: a seven year randomised study of the levonorgestrel 20 microgram/day. LNG-20 and the copper Ag IUDs. Contraception 1991; 44: 473-480.
7. World Health Organisation (1987). Mechanism of action, safety and efficacy of intrauterine devices. Technical Report Series 753. Geneva: WHO.
8. Silverberg SG, Haukkamaa M, et al. Endometrial morphology during long-term use of levonorgestrel-releasing intrauterine devices Int J Gynecol Pathol 1986; 5(3): 235-241.
9. Sivin I, Stern J, and the International Committee for Contraception Research. Health during prolonged use of Levonorgestrel 20 micrograms/day and the Copper TCu 380 AG intrauterine contraceptive devices: a mulucentre study. Fert Steril 1994; 61: 70-77.
10. Chi I-c. The T Cu-380A (Ag). MLCu375, and Nova T IUDs and the IUD daily releasing 20 micrograms levonorgestrel - four pillars of IUD contraception for the nineties and beyond? Contraception 1993; 47: 325-347.
11. Sivin I, et al. Prolonged intrauterine contraception: a seven-year randomised study of the levonorgestrel 20 micrograms/day (LNG 20) and the Copper T380 Ag IUDs. Contraception 1979; 44(5): 473-480.
12. Tietze C, Lewitt S. Recommended procedures for the statistical evaluation of intrauterine contraception. Studies in Fam Plann 1973; 4(2): 35-42.
13. Tattersall J, Allison O, Blacksell S, in collaboration with the UK Family Planning Research Network. The Levonorgestrel Intrauterine System in routine use: experiences of insertion. Acta Obstet Gynecol Scand 1997; 76(Suppl. 167:4): P72.31, pp51.
14. Vessey M P, Johnson B, et al. Outcome of pregnancy in women using an intrauterine device. Lancet 1974; 1: 495-498.
15. Bounds W. Clinical experience with a levonorgestrel-releasing intrauterine contraceptive device as a contraceptive and in the treatment of menorrhagia. Br J Fam Plann 1993; 19: 193-194.
16. Sturridge F, Guillebaud J. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system. Drug Safety 1996; 15(6): 430-440.
17. Royal College of Obstetricians and Gynaecologists. The Management of Menorrhagia in Secondary Care. Evidence-based Clinical Guidelines No5. July 1999.
18. Weiner E, Victor A, Johansson EDB. Plasma levels of d-norgestrel after oral administration. Contraception 1976; 14: 563-570.
19. Fotherby K. Levonorgestrel, clinical pharmacokinetics. Clin Pharmacokinet 1995; 28(3): 203-215.
20. Nilsson CG, Lahteenmaki PIA, et al. Sustained intrauterine release of levonorgestrel. Fert Steril 1986; 45: 805-807.
21. Korba VD, Paulson SR. Five years of fertility control with microdose Norgestrel: an updated clinical review. J of Reprod Med 1974; 13: 71-75.
22. Scharff H J. Clinical experience with Microlut. Schering Med News 1972; 1: 2-8.
23. Bromham DR. Intrauterine contraceptive devices-a reappraisal. Br Med Bull 1993; 49: 100-123.
24. Farley TMH, Rosenberg MJ, Rowe P. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 1992; 339: 785-788.
25. Chi I-c. An evaluation of the levonorgestrel-releasing IUD: Its advantages and disadvantages when compared to the copper releasing IUDs. Contraception 1991; 44: 573-588.
26. Robinson GE, Bounds W, Kubba A, et al. Functional ovarian cysts associated with the levonorgestrel releasing intrauterine device. Br J Fam Plann 1989; 14:131-132.